<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04977401</url>
  </required_header>
  <id_info>
    <org_study_id>P2021-208</org_study_id>
    <nct_id>NCT04977401</nct_id>
  </id_info>
  <brief_title>EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection</brief_title>
  <acronym>EPSILON</acronym>
  <official_title>EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection: a Randomized Controlled Multicentric Trial (EPSILON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EPSILON study aims to comparatively evaluate the submucosal injection using ORISETM gel&#xD;
      and glycerol during an ESD procedure in a specific population with superficial gastric and&#xD;
      rectal (pre)neoplastic lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traditionally, ESD requires the injection of some colloidal solution (glycerol, geloplasma,&#xD;
      hydroxyethylstrach, etc.) in the submucosal layer in order to obtain long lifting effect and&#xD;
      thus allowing the endoscopist to dissect under the lesion. Alternatives to colloid-solution&#xD;
      assisted ESD have also been developped: pocket creation method and saline-immersion ESD.&#xD;
&#xD;
      Recently, other colloidal solutions have arrived on the market, such as gel (ORISETM gel) in&#xD;
      order to improve the lifting during ESD.Our preliminary experience using ORISETM gel as a&#xD;
      lifting solution for ESD was unexpectedly favourable with few per-procedural bleeding, quick&#xD;
      time and facility.&#xD;
&#xD;
      As the spread of ESD is closely associated to its easiness, procedure duration (itself&#xD;
      associated to number of procedural bleedings and instruments change through the operating&#xD;
      channel) and safety, we sought to study comparatively two submucosal solutions when&#xD;
      conducting ESD in a specific population presenting gastric or rectal superficial lesions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A multicentric, randomized, open label prospective study:&#xD;
All subjects with indications of gastric and rectal ESD undergo screening and baseline visit&#xD;
Informed consent is obtained when scheduling the ESD procedure&#xD;
Randomization is made at the time of the ESD procedure after confirmation of the indication&#xD;
ESD is performed using a 25 G needle, a dual-knife-J with glycerol (standard solution) or ORISETM gel in order to remove the lesion en-bloc. Additional saline injection through the electrosurgical knife will be left at the discretion of the endoscopist&#xD;
A follow-up visit is scheduled at 2-4 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>A computer-based block randomization scheme will be created using block randomization and stratifying by center and by organ type (stomach/rectum). Data will be collected through a printed CRFs and then anonymized and entered into a central web based secured platform.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Increase the dissection speed of the ESD procedure</measure>
    <time_frame>At day 0 during ESD</time_frame>
    <description>Increase the dissection speed of the ESD procedure (defined as the dissected surface (mm2)/ESD duration (min). The dissected surface is defined as maximal diameter of specimen (mm) x perpendicular minimal diameter of specimen (mm) measured on ex-vivo pinned stretched specimen onto a cork. ESD duration is defined as the time from first submucosal injection to final cut time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total procedure duration</measure>
    <time_frame>At day 0 during ESD</time_frame>
    <description>Total procedure duration (from scope insertion to scope retrieval) (min)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of per-procedural bleeding</measure>
    <time_frame>At day 0 during ESD</time_frame>
    <description>Number of per-procedural bleeding (+ severity scale: oozing / severe non pulsating/ severe pulsating)</description>
  </other_outcome>
  <other_outcome>
    <measure>Total hemostatic time</measure>
    <time_frame>At day 0 during ESD</time_frame>
    <description>Total hemostatic time (addition of each hemostasis time for each per-procedural bleeding)</description>
  </other_outcome>
  <other_outcome>
    <measure>Need for haemostatic forceps</measure>
    <time_frame>At day 0 during ESD</time_frame>
    <description>Need for haemostatic forceps during ESD</description>
  </other_outcome>
  <other_outcome>
    <measure>Difficulty of the dissection</measure>
    <time_frame>At day 0 during ESD</time_frame>
    <description>Difficulty of the dissection (scale) (very easy / easy / moderately difficult / difficult / very difficult)</description>
  </other_outcome>
  <other_outcome>
    <measure>Amount of submucosal solution</measure>
    <time_frame>At day 0 during ESD</time_frame>
    <description>Amount of submucosal solution (glycerol or gel) used for ESD in ml</description>
  </other_outcome>
  <other_outcome>
    <measure>Combined use of saline</measure>
    <time_frame>At day 0 during ESD</time_frame>
    <description>Combined use of saline through the knife during ESD (number and ml)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of needle injection dots</measure>
    <time_frame>At day 0 during ESD</time_frame>
    <description>Number of needle injection dots during ESD (initially / during ESD)</description>
  </other_outcome>
  <other_outcome>
    <measure>Need to adjust electrosurgical settings</measure>
    <time_frame>At day 0 during ESD</time_frame>
    <description>Need to adjust electrosurgical settings during ESD</description>
  </other_outcome>
  <other_outcome>
    <measure>Clear visualisation of the plane of dissection during ESD (scale).</measure>
    <time_frame>At day 0 during ESD</time_frame>
    <description>Clear visualisation of the plane of dissection during ESD (scale). The scale will be defined according the endoscopists evaluation of the delineation between the submucosa ad the underlying muscular layer:&#xD;
Very-good visualization: clear delineation between the two layers with clear visualization of the blood vessels.&#xD;
Good visualization: mostly clear delineation between the two layers, but with blurred regions&#xD;
Bad visualization: delineation between the two layers is unclear (i.e.:&#xD;
fibrosis)</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of en-bloc dissection</measure>
    <time_frame>At day 0 during ESD</time_frame>
    <description>Rate of en-bloc dissection (defined as endoscopic resection of the targeted area in one bloc)</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of complete endoscopic resection</measure>
    <time_frame>At day 0 during ESD</time_frame>
    <description>Rate of complete endoscopic resection (defined as endoscopic evaluation of complete removal of the targeted area in the treated organ)</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality assessment of the pathological specimen</measure>
    <time_frame>At day 0 during ESD</time_frame>
    <description>Quality assessment of the pathological specimen (absolute measure of the depth of resected submucosa on the specimen, rate of clear (horizontal and vertical) margins)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>From ICF signature up to 2-3 weeks follow-up</time_frame>
    <description>Adverse events:&#xD;
Per-procedural (incidence of all adverse technical events during the procedure)&#xD;
Early (clinical and laboratory at 24 h post procedure according to CTCAE v 5.0)&#xD;
Late (clinical at 2-3 weeks follow-up)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Early Gastric Cancer</condition>
  <condition>Rectal Polyp</condition>
  <arm_group>
    <arm_group_label>Group Glycerol</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Submucosal injection using glycerol during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Gel ORISE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Submucosal injection using ORISETM gel during an ESD procedure in a specific population with superficial gastric and rectal (pre)neoplastic lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic submucosal dissection</intervention_name>
    <description>Dissecting superficial gastric or rectal lesion/polyp after injection of the submucosa for lifting, using a electrosurgical knife through the endoscope</description>
    <arm_group_label>Group Gel ORISE</arm_group_label>
    <arm_group_label>Group Glycerol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>use of Orise Gel as lifting agent for endoscopic submucosal dissection</intervention_name>
    <description>Injection of some colloidal solution (ORISE gel) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.</description>
    <arm_group_label>Group Gel ORISE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>use of glycerol as lifting agent for endoscopic submucosal dissection</intervention_name>
    <description>Injection of some colloidal solution (glycerol) in the submucosal layer in order to obtain long lifting effect and thus allowing the endoscopist to dissect under the lesion.</description>
    <arm_group_label>Group Glycerol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  o Patients must have given written informed consent&#xD;
&#xD;
          -  o Subjects with documented gastric or rectal lesions with indication of endoscopic&#xD;
             removal by ESD, namely:&#xD;
&#xD;
               -  Gastric focal lesion with suspicion of early gastric cancer (low or high grade&#xD;
                  dysplasia with features of early gastric cancer; adenocarcinoma with morphology&#xD;
                  of superficial lesion and work-up of superficial lesion)&#xD;
&#xD;
               -  Rectal polyps (adenoma or superficial carcinoma) from 0 to 15 cm from the anal&#xD;
                  margin; with features being recognized indications of ESD: more than 20mm&#xD;
                  granular LST, more than 20mm non granular LST, more than 20mm villous or bulging&#xD;
                  polyps, Paris 0-IIa+IIc lesions, lesions with suspicious pattern (Kudo Vi / JNET&#xD;
                  2B), lesions with anal canal involvement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who meet any of the following exclusion criteria cannot be enrolled in the&#xD;
             study:&#xD;
&#xD;
               -  Gastric and rectal neuroendocrine tumour (NET) with indication of ESD will be&#xD;
                  excluded&#xD;
&#xD;
               -  Gastric and rectal lesions with indication of ESD but strong fibrosis due to&#xD;
                  previous partial resection will be excluded&#xD;
&#xD;
               -  Subject is currently enrolled in another confounding research&#xD;
&#xD;
               -  Subjects with any other location of ESD (esophagus, duodenum and colon) will not&#xD;
                  be included.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Lemmers, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasme Hospital, Université Libre de Bruxelles. (ULB), Brussels, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnaud Lemmers, MD,PhD</last_name>
    <phone>+325556559</phone>
    <email>arnaud.lemmers@erasme.ulb.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dimitri Oger</last_name>
    <phone>+3225555828</phone>
    <email>dimitrioger@erasme.ulb.ac.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sloan Memorial Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Makoto Nishimura, MD</last_name>
      <email>nishimum@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Laura Kakalios</last_name>
      <email>kakaliol@mskcc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Makoto Nishimura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Galen Leung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital, Université Libre de Bruxelles. (ULB)</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Arnaud Lemmers, MD, PhD</last_name>
      <phone>+3225556559</phone>
      <email>arnaud.lemmers@erasme.ulb.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Dimitri Oger</last_name>
      <phone>+3225555828</phone>
      <email>dimitri.oger@erasme.ulb.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Vincent Huberty, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana-Maria Bucalau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40217</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Torsten Beyna, MD, PhD</last_name>
      <email>Torsten.Beyna@evk-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <email>Studien@evk-duesseldorf.de</email>
    </contact_backup>
    <investigator>
      <last_name>Torsten Beyna, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Horst Neuhaus, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <contact>
      <last_name>Naohisa Yahagi, MD, PhD</last_name>
      <email>yahagi-tky@umin.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Naohisa Yahagi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matsura Noriko, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Motohiko Kato, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cao Y, Liao C, Tan A, Gao Y, Mo Z, Gao F. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy. 2009 Sep;41(9):751-7. doi: 10.1055/s-0029-1215053. Epub 2009 Aug 19.</citation>
    <PMID>19693750</PMID>
  </reference>
  <results_reference>
    <citation>Fujishiro M. Perspective on the practical indications of endoscopic submucosal dissection of gastrointestinal neoplasms. World J Gastroenterol. 2008 Jul 21;14(27):4289-95. Review.</citation>
    <PMID>18666315</PMID>
  </results_reference>
  <results_reference>
    <citation>Kodashima S, Fujishiro M, Yahagi N, Kakushima N, Omata M. Endoscopic submucosal dissection using flexknife. J Clin Gastroenterol. 2006 May-Jun;40(5):378-84.</citation>
    <PMID>16721217</PMID>
  </results_reference>
  <results_reference>
    <citation>Park YM, Cho E, Kang HY, Kim JM. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc. 2011 Aug;25(8):2666-77. doi: 10.1007/s00464-011-1627-z. Epub 2011 Mar 18. Review.</citation>
    <PMID>21424201</PMID>
  </results_reference>
  <results_reference>
    <citation>Lian J, Chen S, Zhang Y, Qiu F. A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer. Gastrointest Endosc. 2012 Oct;76(4):763-70. doi: 10.1016/j.gie.2012.06.014. Epub 2012 Aug 9.</citation>
    <PMID>22884100</PMID>
  </results_reference>
  <results_reference>
    <citation>Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, Repici A, Vieth M, De Ceglie A, Amato A, Berr F, Bhandari P, Bialek A, Conio M, Haringsma J, Langner C, Meisner S, Messmann H, Morino M, Neuhaus H, Piessevaux H, Rugge M, Saunders BP, Robaszkiewicz M, Seewald S, Kashin S, Dumonceau JM, Hassan C, Deprez PH. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015 Sep;47(9):829-54. doi: 10.1055/s-0034-1392882. Epub 2015 Aug 28.</citation>
    <PMID>26317585</PMID>
  </results_reference>
  <results_reference>
    <citation>Fujishiro M, Yahagi N, Kashimura K, Mizushima Y, Oka M, Enomoto S, Kakushima N, Kobayashi K, Hashimoto T, Iguchi M, Shimizu Y, Ichinose M, Omata M. Comparison of various submucosal injection solutions for maintaining mucosal elevation during endoscopic mucosal resection. Endoscopy. 2004 Jul;36(7):579-83.</citation>
    <PMID>15243878</PMID>
  </results_reference>
  <results_reference>
    <citation>Castro R, Libânio D, Pita I, Dinis-Ribeiro M. Solutions for submucosal injection: What to choose and how to do it. World J Gastroenterol. 2019 Feb 21;25(7):777-788. doi: 10.3748/wjg.v25.i7.777. Review.</citation>
    <PMID>30809079</PMID>
  </results_reference>
  <results_reference>
    <citation>Takezawa T, Hayashi Y, Shinozaki S, Sagara Y, Okada M, Kobayashi Y, Sakamoto H, Miura Y, Sunada K, Lefor AK, Yamamoto H. The pocket-creation method facilitates colonic endoscopic submucosal dissection (with video). Gastrointest Endosc. 2019 May;89(5):1045-1053. doi: 10.1016/j.gie.2019.01.022. Epub 2019 Feb 1.</citation>
    <PMID>30716306</PMID>
  </results_reference>
  <results_reference>
    <citation>Yamamoto H, Hayashi Y, Despott EJ. The pocket-creation method for endoscopic submucosal dissection combined with saline-immersion: another potential option to overcome challenges in colorectal endoscopic submucosal dissection. Gastrointest Endosc. 2019 Aug;90(2):288-289. doi: 10.1016/j.gie.2019.04.244.</citation>
    <PMID>31327340</PMID>
  </results_reference>
  <results_reference>
    <citation>Endoscopic Classification Review Group. Update on the paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy. 2005 Jun;37(6):570-8. Review.</citation>
    <PMID>15933932</PMID>
  </results_reference>
  <results_reference>
    <citation>Hewett DG, Kaltenbach T, Sano Y, Tanaka S, Saunders BP, Ponchon T, Soetikno R, Rex DK. Validation of a simple classification system for endoscopic diagnosis of small colorectal polyps using narrow-band imaging. Gastroenterology. 2012 Sep;143(3):599-607.e1. doi: 10.1053/j.gastro.2012.05.006. Epub 2012 May 15.</citation>
    <PMID>22609383</PMID>
  </results_reference>
  <results_reference>
    <citation>Sano Y, Tanaka S, Kudo SE, Saito S, Matsuda T, Wada Y, Fujii T, Ikematsu H, Uraoka T, Kobayashi N, Nakamura H, Hotta K, Horimatsu T, Sakamoto N, Fu KI, Tsuruta O, Kawano H, Kashida H, Takeuchi Y, Machida H, Kusaka T, Yoshida N, Hirata I, Terai T, Yamano HO, Kaneko K, Nakajima T, Sakamoto T, Yamaguchi Y, Tamai N, Nakano N, Hayashi N, Oka S, Iwatate M, Ishikawa H, Murakami Y, Yoshida S, Saito Y. Narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team. Dig Endosc. 2016 Jul;28(5):526-33. doi: 10.1111/den.12644. Epub 2016 Apr 20. Review.</citation>
    <PMID>26927367</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasme University Hospital</investigator_affiliation>
    <investigator_full_name>Lemmers Arnaud</investigator_full_name>
    <investigator_title>MD, PhD, Professor, Head of Clinic, Endoscopy Unit</investigator_title>
  </responsible_party>
  <keyword>ESD (endoscopic submucosal dissection)</keyword>
  <keyword>Rectum polyp</keyword>
  <keyword>early gastric cancer</keyword>
  <keyword>endoscopic resection</keyword>
  <keyword>submucosal injection solution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 21, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT04977401/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 21, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT04977401/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

